Therapeutic Advances in Neurological Disorders
Review
Best practice in the management of behavioural and psychological
symptoms of dementia
Olivier Pierre Tible, Florian Riese, Egemen
Savaskan* and Armin von Gunten*
Abstract: Behavioural and psychological
symptoms of dementia (BPSD) occur in most patients with dementia. They cause
great suffering in patients and caregivers, sometimes more so than the
cognitive and functional decline inherent to dementia. The clinical features of
BPSD include a wide variety of affective, psychotic and behavioural symptoms
and signs.
The causes and risk factors for BPSD are
multiple and include biological, psychological and environmental variables.
Frequently, their combination, rather than any specific factor, explains the occurrence
of BPSD in an individual patient. Thus, a sound etiopathogenetic investigation
including the patient and the family or care team is essential. The aim is to
develop an individualized treatment plan using a therapeutic decision tree
modified by the individual and environmental risk profile. Still, treatment may
be difficult and challenging. Clinical empiricism often steps in where evidence
from controlled studies is lacking. Psychosocial treatment approaches are
pivotal for successful treatment of BPSD. Often a combination of different
non-pharmacological approaches precedes drug treatment (most of which is
off-label). Regular assessments of the treatment plan and any prescriptions
must be carried out to detect signs of relapse and to stop any medicines that
may have become inappropriate. Even with optimal management, BPSD will not
disappear completely in some cases and will remain challenging for all involved
parties. This article is a narrative review based closely on the
interprofessional Swiss recommendations for the treatment of BPSD. To establish
the recommendations, a thorough research of the literature has been carried
out. Evidence-based data were provided through searches of Medline, Embase, ISI
and Cochrane- Database research. Evidence categories of the World Federation of
Biological Societies were used. Additionally, the clinical experience of Swiss
medical experts was considered.
Keywords: attachment, BPSD, environmental
factors, etiopathogenetic, individualized treatment, personality
Received: 24 January 2017; revised
manuscript accepted: 24 April 2017
Introduction
The term behavioural and psychological symptoms
of dementia (BPSD; also termed neuropsychiatric symptoms) describes the
heterogeneous group of symptoms and signs of disturbed perception, thought
content, mood or behaviour that frequently occur in patients with dementia.1,2
Throughout the course of their dementia, the vast majority of patients will
develop one or more BPSD.1-6 BPSD can have serious consequences.
They are associated with worsening cognition and
progression to more severe stages of
dementia.7 BPSD also lead to individual suffering and impact the
caregiver burden.8 Furthermore, they increase the risk for secondary
complications such as falls and fractures leading to emergency room admis-
sions,9 and ultimately institutionalization.10,11
Finally, BPSD result in higher costs of therapy and caregiving.12,13
The treatment of patients with BPSD can be
challenging for physicians and healthcare teams. The
Ther Adv Neurol Disord 1-13
DOI: 10.1177/ 1756285617712979
© The Author(s), 2017.
Reprints and permissions: http://www.sagepub.co.uk/
journalsPermissions.nav
Correspondence to:
Olivier Pierre Tible
Department of Psychiatry, Service
Universitaire de Psychiatrie de l'Age Avance (SUPAA), Lausanne University
Hospital, CH- 1008 Prilly, Switzerland olivier.tible@chuv.ch
Armin von Gunten
Department of Psychiatry, Service
Universitaire de Psychiatrie de l'Age Avance (SUPAA), Lausanne University Hospital,
Prilly, Switzerland
Florian Riese
Department of Geriatric Psychiatry,
University Hospital of Psychiatry, Zurich, Switzerland University Research
Priority Programme 'Dynamics of Healthy Aging', University of Zurich, Zurich,
Switzerland
Egemen Savaskan
Department of Geriatric Psychiatry,
University Hospital of Psychiatry, Zurich, Switzerland
*These authors have equally contributed to
this article
1
Therapeutic Advances in Neurological
Disorders 00(0)
etiopathogenesis of BPSD is often complex,
with multiple contributing direct factors and indirect mediators. Biological
factors (e.g. brain changes, comorbidities, medication) may interact with psychological
(e.g. personal life history, personality) or social (support network, living
arrangements) aspects. Consequently, treatment should be guided by a
comprehensive etiopathogenetic assessment. Currently, there is limited evidence
for symptomatic treatments and the available evidence-based options are only
moderately effective. Psychosocial, that is non-pharmacological, approaches
should be considered the mainstay of therapy and are complemented by
psychotropic medication only if unavoidable. Ideally, the available treatment
algorithms are used to devise an individualized treatment plan informed by a
multifaceted understanding of the patient’s situation, clinical experience and
expert knowledge.
The clinical presentations of BPSD include
apathy, depression, anxiety, delusions, hallucinations, sexual or social
disinhibition, sleep-wake cycle disturbances, aggression, agitation and other
behaviours considered inappropriate.14 There are several instruments
to systematically assess the presence and severity of BPSD,15 among
which the Neuropsychiatric Inventory (NPI)16 and Behavioral
Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD)17 are
recommended.18 Some BPSD tend to cluster together, usually into
four clusters - that is, the affective, psychotic, hyperactive and apathetic
clusters.1,19 In a population-based study, the cumulative
incidence of having one or more NPI-measured BPSD from the onset of cognitive
symptoms was 80%,20 indicating that occurrence of BPSD has to be
expected throughout the course of dementia. Apathy, depression, anxiety and
agitation were found to be the most frequent forms of BPSD.2,20,21
However, a recent systematic review revealed substantial variation in the
reported prevalence, incidence and longitudinal course between different
studies.22 In an individual patient, the type and severity of BPSD
tend to change over time, but some forms such as wandering seem to be more
persistent.22 Overall, the ‘natural course’ of BPSD over time is
still largely unknown.
Most patients with dementia have depressive
symptoms and signs at some point in time over
the course of dementia (nearly 80% over the
past 5 years). Some patients may present with a major depressive disorder
(10-20%).1 A history of depressive disorder is likely to increase
the risk of major depressive disorder during dementia. Insomnia, changes in
circadian rhythm and anxiety may accompany depressive symptoms. Abnormalities
in the serotonin, dopamine or epinephrine systems, frontal atrophy, and
amygdala reactivity may be some of the neurobiological underpinnings of
depressive features.
Another condition that should be considered
is the Charles Bonnet syndrome, which is due to an eye disease. Visual
hallucinations in Charles Bonnet syndrome are usually of short duration and
patients are aware that they are not real; these hallucinations are often well
tolerated by the patient and therefore may not need treatment other than that
prompted by the underlying eye disease. In some instances, carbamazepine may
be useful.23 Auditory hallucinations must evoke an underlying
psychotic state not primarily explained by dementia, and usually need
treatment.
In an inpatient clinical setting, agitation
is often the most challenging BPSD since it may severely disrupt patient care.
Hence, most treatment trials for BPSD have been performed for agitation.
Agitation refers to an ill-defined spectrum of aberrant hyperactive motor
behaviours (such as wandering, leaving home) and physically or verbally aggressive
behaviours such as rejection of care. Only recently a provisional consensus
definition has been suggested for agitation in cognitive disorders.24
Beyond the behavioural phenotype, this new definition emphasizes the emotional
distress and excess disability that is associated with agitation. Agitation may
worsen during the evening hours, a phenomenon referred to as ‘sundowning’.25
Since delusions in dementia are found to
sometimes correspond to reality or to be neither incorrigible nor held with
absolute certainty, they may not represent psychotic symptoms in a narrow sense
and should certainly not preclude the attempt to understand their meaning.26
2
OP TibLe, F Riese et al.
Patient factors
Unmet needs (m)
Pain (m)
Acute medical problems (m) Comorbidities
(pm)
Type of dementia (u)
Dementia stage (u)
Brain changes (u) Neurotransmitter changes
(pm) Genetic makeup (u)
Personality (u)
Life history (u)
Knowledge about condition (m) Caregiver
distress (m) Over-/understimulation (m) Lack of routines (m)
Caregiving quantity (pm) Caregiving quality
(pm) Caregiver's knowledge (m) Infrastructure of care facility (u) Life event /
separation (u) Family dynamics (pm)
Behavioural and psychological symptoms of dementia
Figure 1. Simplified etiopathogenetic model
of BPSD.
m, modifiable; pm, potentially modifiable;
u, unmodifiable.
In terms of content, delusions in dementia
are frequently persecutory in nature or revolve around theft - that is, lost
objects,27 danger, abandonment and the idea that one’s house is not
one’s home.26 Notably, only about half of the cases of delusions
appear to lead to discomfort and are associated with behavioural disturbances.28
A frequent subtype of delusions in dementia is the misidentification syndromes
in which a patient consistently misidentifies persons, places, objects or
events (e.g. Capgras syndrome).29 Sensory impairment is widely considered
a contributory factor in the development of certain delusions in dementia, most
obviously in cases of Charles Bonnet syndrome in the context of visual impairment.
Apathy is usually defined as loss of
motivation and decreased interest in daily activities.30 In the most
severe forms, the affected patients may be unable to initiate almost any kind
of directed activity, thus spending most of the day in bed or sitting in a
chair. Apathy is one of the most frequent forms of BPSD and is associated with
poor prognosis and increased mortality.31,32 However,
apathy rarely leads to hospital admissions since it is not usually as
disruptive for caregivers as other BPSD.
Sleep problems and disturbances of circadian rhythms
Sleep problems are both risk factors and
frequent symptoms of dementias and may also arise from comorbidities.33,34
Sleep problems are a major contributor to caregiver burden. Even though the
clinical need for effective treatments is high, the evidence base for
treatments is limited.35 In dementia with Lewy bodies (DLB), REM
(rapid eye movement) sleep behaviour disorder (RBD) can be an early sign of the
disease, with daytime fluctuations of attention, greater number of daytime
naps and longer night sleeps.36,37 RBD can also be seen
in other synucleopathies such as Parkinson’s disease and multiple system
atrophy. In frontotemporal dementia (FTD), RBD is rare but may be confused with
excessive nocturnal activity due to disturbed circadian rhythmicity.38
More often than not the etiopathogenesis of
BPSD is complex and multifactorial.1 For the sake of didactic
simplicity and practicability, the causative and contributing factors can be
divided into biological, psychological and social or environmental factors
(Figure 1).
Based on this perspective, a model for
etiopatho- genetic treatment of BPSD can be derived.
3
Therapeutic Advances in Neurological
Disorders 00(0)
Brain lesions and type of dementia.
Dementia- related brain lesions and changes in neurotransmission have been
linked to specific BPSD.1 Their effect may be moderated by other
biological factors such as comorbidity or treatment-related factors, as well
as the individual’s genetic make-up.
In the course of Alzheimer’s disease (AD),
psychotic symptoms were found to be associated with neuronal loss in several
brain regions, including the hippocampus, parahippocampal gyrus and various
brain stem nuclei.39 In mixed (vascular and AD) dementia, vascular
factors may trigger hallucinations, illusions, anxiety, dysphoria, aggression
and delirium.39-41
Besides the aphasic forms, FTD is defined
by behavioural features (bv-FTD or behavioural variant of FTD). These features
are present from the early stages of the disorder and include loss of interest
and apathy, as well as disinhibition, including inappropriate sexual behaviour
and impulsive behaviours that are more frequent than in other dementias.39
Both sporadic and familial forms of FTD have been described.42,43
Similar to AD, a number of neurotransmitter and cortico- limbic changes have
been linked to behavioural disruptions in FTD.1,42,44
Clearly, FTD is an important differential diagnosis, particularly in the early
dementia stages. It is different from the frontal variant of AD,45
and BPSD in FTD are probably less amenable to efficient treatment than in other
forms of dementia.
Many neuroanatomical studies have been conducted
that link BPSD to dementia-related brain lesions. For example, apathy was
associated with hypoperfusion in the anterior cingulate cortex and
fronto-subcortical structures,1,46 giving rise to a
disconnection model of apathy between the pre- frontal cortex and the
mediodorsal and anterior thalamic nuclei.47 However, hypoperfusion
in frontal or temporal lobes was also found to correlate with aggression and
psychosis.1 A variety of functional and structural parameters
including, for example, white matter changes,48 atrophy patterns and
vascular damage contribute to BPSD.48,49
Changes in neurotransmission and neuromodulation.
Changes in neurotransmission and neuromodulation have been found to correlate
with BPSD. In AD, changes in cholinergic activity in the frontal and temporal
cortices may be linked to aberrant motor activity and aggressive
behaviour.50,51 Visual
hallucinations in DLB seem to be linked with cholinergic deficits in the
temporal cortex.50 In AD, aggression was reported to be related to
reduced dopamine concentration in the temporal cortex.44 Decreased
norepinephrine neurons in the locus coeruleus are accompanied by aggressive
behaviour.1,52 Similarly, apathy was correlated with dopaminergic
dysfunction in AD.31,53,54 Serotonin
concentration correlated positively with aggressiveness, depressed mood,
anxiety, agitation and restlessness.1 Interestingly, serotonin and,
thus, SSRIs, may improve hippocampal neurogene- sis,55 and synaptic
plasticity and survival of neurons are linked to the glutamatergic pathway.1,56,57
Severe glutamate loss in AD may result in psychotic symptoms. Significant GABA
decrease in the frontal and temporal cortex and high GABA plasma concentration
were found in severe AD that correlated with depression and apathy.1
As drugs acting on the above-mentioned neurotransmitter systems are legion, it
is evident that many of them can either cause or favour the development of BPSD58
or, on the contrary, have a potentially positive influence on them. Further
pathway disorders related to neuromodulator and neuroendocrine systems have
been proposed as correlates of BPSD, as well as circadian rhythms and sleep
disorders,1,59,60 including those of the
hypothalamic-pituitary-adrenal axis or the homocystein metabolism.61
A number of findings suggest a genetic
vulnerability for BPSD, though this field of research is still in its infancy.
As an example, AD subjects who are ApoEe4 carriers had more delusions and
agitation/aggressive behaviours than non-ApoEe4 carriers.62 Given
the implication in BPSD of neurotransmitter changes, it may come as no
surprise that specific polymorphisms may predispose to BPSD.6264
Physical disorders and pain. Physical
disorders are often a central element in the understanding of BPSD and must be
evaluated and treated accordingly.1,6,58,65 Among the most frequent
somatic causes of BPSD are pain, infections, electrolyte imbalances or
metabolic disorders, urinary retention, constipation, cerumen and others. Any
of these may cause BPSD and a thorough medical examination is therefore a
requirement. Especially pain often leads to BPSD of various types, such as
insomnia, aggressiveness or agitation.66 Looking for pain-inducing
factors and eliminating them is pivotal, as
4
OP Tible, F Riese et al.
pain is too often undetected and therefore
undertreated in people with dementia.
Psychological and environmental perspective
Considering BPSD as the result of stressors combined with variable degrees of
vulnerability, it is easy to imagine a host of psychological and systemic
factors (personality, environmental elements both physical and emotional that
contribute to the occurrence of BPSD).
Personality traits. Personality changes
occur when dementia develops. In AD, a predictable change seems to occur
independently of the previous personality, in that neuroticism usually
increases while extraversion, openness and conscientiousness tend to decrease,
with agreeability remaining more stable.67 Furthermore and apart
from its obvious face validity, there is increasing evidence that our
personality - what we are as persons - contributes to the clinical expression
of dementia. Thus, some personality traits may favour, or on the contrary
protect against, BPSD. Thus, in AD, increased neuroticism as a premor- bid
personality trait may be associated with a higher risk for depression,1,65,68,69
and even be a risk factor for cognitive decline and AD.70,71
Patients who have been suspicious or aggressive before dementia starts are more
likely to have BPSD than those without these traits.1,69
However, such correlations have not always been found68 and one of
the more significant limitations of most of the studies currently available is
the use of retrospective personality ratings, subjecting their findings to
possible inaccuracies. Psychiatric diseases may be risk factors for dementia as
this has been established for depression and for BPSD.72
Life events. Stressful life events in
childhood or adulthood may favour BPSD in dementia through, among other
etiopathogenic lines, increased vulnerability related to hippocampal hypotrophy
and behavioural inhibition or insecure attachment.56,73-75
Thus, overt attachment behaviour towards a family member or stranger was
pronounced in old nursing home residents depending on the degree of cognitive
impairment, suggesting that dementia eroded feelings of security and activated
attachment behaviours.76,77 Securely attached individuals with
dementia displayed more positive affect than avoidantly attached individuals.78
Environmental risks. Environmental factors,
both physical and social, are likely to precipitate or buffer BPSD. Thus, lower
levels of BPSD are associated with well-being of nursing home residents, which
is in turn related to environmental characteristics such as unobtrusive safety
features, variety of spaces in environments with calm, single rooms available,
small facility size, and optimization of levels of stimulation, taking into
account the capacities of each patient.1 Similarly, caregiver
distress can exacerbate BPSD and family discord or altered communication in
the family need to be assessed.79,80
The treatment of BPSD is often highly
challenging due to the complex etiopathogenesis of the symptoms and signs and
the multi-morbidity of patients. BPSD management requires both a
patient-centred and caregiver-centred focus and interventions to provide
comfort to patients and alleviate caregiver burden are indispensable. Treating
concomitant somatic diseases can reduce BPSD.6 Effective pain
management is part of a successful BPSD treatment.81 Most expert
recommendations and guidelines prefer non-pharmacological interventions as the
first- line approach.6,82,83 Although the evidence for most
non-pharmacological strategies is weak, their efficacy is supported by
long-standing clinical experience. Pharmacotherapy for BPSD is frequently
provided, but it carries the risk of serious side-effects. Therefore,
non-pharmaco- logical therapies are considered the first choice and should also
be continued when pharmacotherapy is necessary. In order to measure treatment
effects, frequency and severity of BPSD should be quantified at baseline,
possibly using a validated scale or questionnaire, such as the NPI16
or BEHAVE-AD.17,18 Moreover, several algorithms have been
published to guide the diagnostic and therapeutic process for BPSD.14
We suggest using the simplified BPSD-DATE algorithm (describe and measure,
analyse, treat, evaluate; see Figure 2).
Non-pharmacological approaches Due to the
heterogeneous nature of non-pharma- cological interventions, study designs vary
widely in this area and call the generalizability of their results into
question. Compared to pharmacological treatments of BPSD, the evidence base is
much more limited. As of yet, it remains unclear
5
Therapeutic Advances in Neurological
Disorders 00(0)
Behavioural and psychological symptoms of dementia
Describe & measure |
Which behaviour? When? What? How? How
severe? Depressive disorder? Emotional dysreguiation? Insomnia? Safety
concerns? Which context? Which trigger factors ?
Family dynamics? |
|
|
Analyze |
Can you explain this BPSD? What have you learned about the patient?
Which etiopathogenetic factors? Comorbidities? |
|
Work on modifiable factors. |
|
Explain unmodifiable factors to
caregivers. |
|
Support caregivers. |
Treat |
Provide comfort to patient. |
|
Apply non-pharmacological interventions. |
|
Provide empiric pain treatment. |
|
Consider psychopharmacological treatment. |
|
Feasibility? |
Evaluate |
Effectiveness? Sleep quality? Quality of
life? |
Caregiver stress? |
|
|
Unintended consequences or side effects? |
Figure 2. BPSD-DATE interventional
algorithm.
whether or not heterogeneous
non-pharmacolog- ical interventions are efficacious due to a common active but
non-specific ingredient such as positive human interaction. At this point, the
best scientific evidence exists for the use of home- based behavioural
management techniques, caregiver-based interventions or staff training in
communication skills, person-centred care, dementia care mapping against
agitation84,85 and music therapy against agitation and
anxiety.84
Psychosocial interventions. Psychoeducation
for patients and caregivers can reduce BPSD.6,86-88
Multi-component single and group session programmes are effective if they
focus on stressful events, provide both information about the disease and
assistance, and allow for exchange on experiences as to how to deal with daily
problems. Group sessions are more disburdening for caregivers when they include
training in behavioural management techniques.87,88
Coping strategy-based family carer therapy and tailored activities for people
with dementia and their caregivers were found to improve quality of life of
people with dementia living at home.88 Psychoeducational
interventions may be accompanied by social counselling, organizing assistance
and supporting patients and caregivers. Psychosocial interventions, in general,
decrease caregiver depression and can help
delay the institutionalization of patients.89
Nursing care. The need-driven dementia-
compromised behaviour model (NDB) can help understand BPSD as a dysfunctional
expression of needs.90 Based on this model, behavioural analysis in
nursing care may recognize the patient’s urgent needs and reveal their causes.
Some factors causing BPSD, such as pain, hunger or thirst, can be satisfied
immediately. However, personality characteristics and the biography of the
patient, comorbidities and the lack of personal resources can complicate the
course of the disease. The Serial Trial Intervention, based on the NDB model,
uses systematic serial assessments and sequential trials of treatments to
identify and treat unmet needs that may be the underlying cause of BPSD. It has
been shown to reduce BPSD and the use of psychotropic drugs.91
Special nursing care interventions targeting vocalization92 and
sexual disinhibition93 may be helpful to comfort patients.
Physical activity. Regular exercise
improves physical fitness, behaviour, cognition and functioning in older
people.94 There is strong evidence that regular physical activity
improves physical,
6
OP Tible, F Riese et al.
cognitive, functional and behavioural
outcomes also in patients with dementia and can help reduce BPSD.94
Usually, training programmes are based on walking (mobility training) or they
combine walking with different types of isotonic exercises.
Sensory stimulation and music therapy.
Music therapy and multisensorial stimulation techniques such as snoezelen are
effective in reducing agitation and disruptive behaviour during sessions and
immediately after the intervention.6,86 However, there is no
evidence for long-term effects. Biography-related music and combination with
sensory stimulation seem to be more effective.
Reality orientation and cognitive
stimulation therapy. These interventions are based on the idea that a better
orientation in daily life to persons, time or surroundings can improve BPSD.86
Reality orientation therapy is more effective in combination with other
techniques in improving mood and decreasing BPSD. Derived from reality
orientation therapy, cognitive stimulation therapy addresses current problems
in functioning using information processing.86 There are some
immediate effects on BPSD, but the data are inconsistent.
Validation therapy. This patient-centred
technique intends to resolve unfinished conflicts by encouraging and
positively validating expression of feelings.86 There is some
evidence that positively validating expression of feelings may reduce
irritability.
Reminiscence therapy. Reminiscence therapy
uses objects from daily life to stimulate memory and enable people to value
their experiences.86 This intervention can improve mood.
Psychotherapeutic interventions.
Psychological therapies have been investigated in mild to moderate dementia.
The highest level of evidence of efficacy is available for cognitive
behavioural tech- niques.6’86’95’96
Focusing on daily problems, psychotherapeutic interventions are more effective
if caregivers are involved in the process. Combination with psychoeducation
and family counselling improves effectiveness.96,97
Behavioural management techniques improve depression, anxiety, aggression and
agitation in dementia.86 The effect is significant and lasts for
months. Since caregivers can also develop depression during the care process,
they can also benefit from individual psychotherapy.
Since patients with dementia are
particularly vulnerable to adverse effects of drugs, the indication for
psychopharmacotherapy in BPSD has to be discussed very critically.
Multi-morbidity and polypharmacy are interacting factors complicating the use
of pharmacotherapy. Most drugs are not approved for BPSD and their use is
therefore off-label. A detailed clinical and laboratory examination including
history of medication and an electrocardiogram should precede psychopharmacotherapy.
Psychotropic medication use should be limited in time and stopped after a
gradual reduction when BPSD improve. Drug metabolism is altered in elderly
patients and compared to younger patients they usually need lower doses of
psychotropic drugs.
Antidementia drugs. There is some evidence
that cholinesterase inhibitors and memantine may be useful in the management of
BPSD.6,14,98-101 Cho- linesterase inhibitors
may improve affective features in mild to moderate dementia. Cholinesterase
inhibitors and memantine may be effective to treat BPSD. Indeed, donepezil may
alleviate the following BPSD in mild to moderate dementia: apathy, depression,
tension, irritability. There are similar findings for galantamine and
rivastigmine. However, treatment of agitation in AD by donepezil appears to be
inefficient. In conclusion, cholines- terase inhibitors have a certain efficacy
on negative symptoms.6,102 Memantine may be more
effective on positive symptoms including agitation, delusions and
hallucinations, as well as aggression in moderate to severe AD.6,102
However, more recent trials specifically designed for treatment of agitation
challenge these findings as they failed to demonstrate a benefit.99,103,104
Finally, antidementia drugs may reduce the incidence of BPSD. There are also
data that provide some evidence for the preventive efficacy of Ginkgo biloba
extract EGb 761® in the treatment of dementia patients with clinically relevant
BPSD.105
Antidepressants. Depression and anxiety are
among the most common BPSD and an effective antidepressive therapy in dementia
can improve both cognition and affective symptoms as well as other forms of
BPSD, such as agitation and aggressiveness.6,14,106
Tricyclic antidepressants are not recommended because of their anticholinergic
adverse events. SSRIs have reasonable tolera- bility and favourable treatment
response. In dementia, SSRIs (specifically citalopram) are as efficacious as
atypical antipsychotics for treating
7
Therapeutic Advances in Neurological
Disorders 00(0)
agitation.107 SSRIs can be
associated with severe adverse effects such as QT-prolongation and
hyponatraemia.
Antipsychotics. First, it is important to
state that antipsychotics have not been approved for clinical use in dementia,
except for risperidone, at least in some countries. Thus, clinicians ought to
refer to their country’s legislation before introducing an antipsychotic drug
to treat BPSD. Atypical anti- psychotics such as risperidone and aripiprazole
are among the most often (and probably too often) prescribed drugs in BPSD.
They are effective in the treatment of psychotic symptoms, agitation and
aggression.2,14,108,109 Haloperidol may be considered in the
treatment of delirium in dementia, but it is not recommended for a different
use in dementia. Haloperidol is only recommended for delirium because of its
high potential for side-effects. Adverse events associated with atypical antipsychotics
include anticholinergic effects, orthostatic hypotension, seizures, metabolic
syndrome, weight gain, extrapyramidal symptoms, sedation and QT-prolongation.
The increased mortality and the risk for cerebrovascular incidents have led to
a black box warning for the use of antipsychotics in dementia. Antipsy- chotics
can be necessary and helpful in the treatment of certain BPSD, but their use
must be limited in time. Regular evaluations of risks and benefits are
necessary throughout the course of the treatment.110 While the
evidence on the efficacy of quetiapine for BPSD is mixed, it is widely used
clinically.111 Due to its favourable side-effect profile,
particularly regarding extrapyramidal signs, quetiapine may be of particular
value for BPSD, especially in patients with Parkinsonian features, despite
conflicting evidence.112
Mood stabilizers. Although carbamazepine
shows some benefit for agitation in dementia, mood stabilizers are often
associated with severe side- effects.2,14,113
Thus, valproic acid is not recommended. There is some clinical experience and
limited evidence for gabapentine and lamotrigine in the treatment of BPSD.
Benzodiazepines. Evidence for the efficacy
of benzodiazepines in BPSD is lacking. Benzodiazepines are associated with
sedation, dizziness, falls, worsening cognition, respiratory depression,
dependency and paradoxical disinhibition in the elderly. They are thus only
recommended for the management of an acute crisis,6,14 if other methods
fail. Their use must be limited in time and they should not be prescribed as
hypnotics.
Other substances. Hypnotics such as
zopiclone, zolpidem or zaleplone can have similar side- effects as
benzodiazepines.6 They are used for sleep disorders in dementia over
a limited period of time and at small doses. Sedative antidepressants such as
trazodone seem to improve sleep duration. Melatonin and melatonin receptor agonists
can be effective in treating circadian sleep
disorders.34,35
Biological therapies
Light therapy (in the morning) and light
therapy in combination with melatonin (at bedtime) may be useful to treat sleep
or circadian rhythm disorders, ‘sundowning’ and day sleepiness,114
but sleep deprivation is not recommended in BPSD.6 Indeed, there is
a higher risk of agitation and other BPSD may appear due to insomnia.65
Electroconvulsive therapy may be helpful in
individual situations. Similarly, repeated transcranial magnetic stimulation
may become a useful method, but the study of this method to treat BPSD is still
in its infancy.
BPSD occur on an almost regular basis as
dementia evolves, regardless of the dementia type. BPSD are a heterogeneous
group of symptoms and signs, but all of them may cause significant suffering
in patients and caregivers. The causes of and risk factors for BPSD are
multiple, even in a single patient, with interacting biological, psychological
and social/environmental causes and vulnerability factors. Taking a detailed
history and performing a sound clinical investigation including the patient and
their family or care team are essential. In order to arrive at an individualized
treatment plan, a therapeutic decision tree should be established taking into
account the patient’s individual and their environmental risk profile.
Psychosocial treatments are pivotal. Often, combining different
non-pharmacological approaches precedes drug treatment that can be added if
required. Consequently, an interventional algorithm is proposed to take care
of patients suffering BPSD (Figure 2). Regular assessments of the treatment
plan and any prescriptions must be carried out to detect signs of relapse and
to stop any drug that has become inappropriate. Even with optimal management,
BPSD will not disappear completely in some cases and will remain challenging
for all involved parties.
8
OP Tible, F Riese et al.
This research received no specific grant
from any funding agency in the public, commercial or not- for-profit sectors.
Conflict of interest statement
The authors declare that there is no
conflict of interest.
1. International
Psychogeriatric Association. The IPA complete guides to behavioral and
psychological symptoms of dementia. Milwaukee, WI: International
Psychogeriatric Association, 2010, www.ipa-online.org/publications/guides-to-bpsd
(accessed 30 September 2010).
2. Steinberg M,
Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric
symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008;
23:
170-177.
3. Devshi R, Shaw
S, Elliott-King J, et al. Prevalence of behavioural and psychological symptoms
of dementia in individuals with learning disabilities. Diagnostic 2015; 5:
564-576.
4. Kales HC,
Gitlin LN and Lyketsos CG. Management of neuropsychiatric symptoms of dementia
in clinical settings: recommendations from a multidisciplinary expert panel.
Similar to DICE (diagnose, investigate, create, evaluate). J Am Geriatr Soc
2014; 62: 762-769.
5. Perez Romero A
and Gonzalez Garrido S. The importance of behavioral and psychological symptoms
in Alzheimer’s disease. Neurologia. Epub ahead of print 26 April 2016. DOI:
10.1016/j.nrl.2016.02.024.
6. Savaskan E,
Bopp-Kistler I, Buerge M, et al. Therapy guidelines for the behavioural and
psychological symptoms of dementia. Praxis 2014; 103: 135-148.
7. Canevelli M,
Adali N, Cantet C, et al. Impact of behavioral subsyndromes on cognitive
decline
in Alzheimer’s disease: data from the ICTUS
study. J Neurol 2013; 260: 1859-1865.
8. Feast A,
Moniz-Cook E, Stoner C, et al. A systematic review of the relationship between
behavioral and psychological symptoms (BPSD) and caregiver well-being. Int
Psychogeriatr 2016; 28: 1761-1774.
9. Nourhashemi
F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital
admissions of patients with Alzheimer
disease. Alzheimer Dis Assoc Disord 2001;
15: 21-25.
10. Toot S,
Swinson T, Devine M, et al. Causes of nursing home placement for older people
with dementia: a systematic review and metaanalysis. Int Psychogeriatr 2016;
3: 1-14.
11. Yafee K, Fox
P, Newcomer R, et al. Patient and caregiver characteristics and nursing home
placement in patients with dementia. JAMA 2002; 287: 2090-2097.
12. Beeri MS,
Werner P, Davidson M, et al.
The cost of BPSD in community dwelling
Alzheimer’s disease patients. Int J Geriatr Psychiatry 2002; 17: 403-408.
13. Kraft E,
Marti M, Werner S, et al. Cost of dementia in Switzerland. Swiss Med Wkly 2010;
140: w13093.
14. Kales HC,
Gitlin LN and Lyketsos CG. Assessment and management of behavioral and
psychological symptoms of dementia. BMJ 2015; 350: h369.
15. Gitlin LN,
Marx KA, Stanley IH, et al.
Assessing neuropsychiatric symptoms in people
with dementia: a systematic review of measures. Int Psychogeriatr 2014; 26:
1805-1848.
16. Cummings JL,
Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment
of psychopathology in dementia. Neurology 2014; 44: 2308-2314.
17. Reisberg B,
Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease:
phenomenology and treatment. J Clin Psychiatry 1987; 48(Suppl.): 9-15.
18. Jeon YH,
Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral
disturbances associated with dementia. Am J Geriatr Psychiatry 2011; 19:
403-415.
19. Aalten A,
Verhey FR, Boziki M, et al. Consistency of neuropsychiatric syndromes across
dementias: results from the European Alzheimer Disease Consortium. Part II.
Dement Geriatr Cogn Disord 2008; 25: 1-8.
20. Lyketsos CG,
Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia
and mild cognitive impairment: results from the Cardiovascular Health Study.
JAMA 2002; 288: 1475-1483.
21. Mega MS,
Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in
Alzheimer’s disease. Neurology 1996; 46: 130-135.
22. Van der Linde
RM, Dening T, Stephan BCM, et al. Longitudinal course of behavioural and
9
Therapeutic Advances in Neurological
Disorders 00(0)
psychological symptoms of dementia:
systematic review. Br JPsychiatry 2016; 209: 366-377.
23. Elflein HM,
Rudy M, Lorenz K, et al. Charles Bonnet’s syndrome: not only a condition of the
elderly. Graefes Arch Clin Exp Ophthalmol 2016;
254: 1637-1642.
24. Cummings J,
Mintzer J, Brodaty H, et al.
Agitation in cognitive disorders:
International Psychogeriatric Association provisional consensus clinical and
research definition. Int Psychogeriatr 2015; 27: 7-17.
25. Gnanasekaran
G. ‘Sundowning’ as a biological phenomenon: current understandings and future
directions: an update. Aging Clin Exp Res 2016; 28: 383-392.
26. Cohen-Mansfield
J, Golander H, Ben-Israel J, et al. The meaning of delusions in dementia: a
preliminary study. Psychiatry Res 2011; 189:
97-104.
27. Cipriani G,
Danti S, Vedovello M, et al.
Understanding delusion in dementia: a
review.
Geriatr GerontolInt 2014; 14: 32-39.
28. Cohen-Mansfield
J, Cohen R, Golander H, et al. The impact of psychotic symptoms on the persons
with dementia experiencing them. Am J Geriatr Psychiatry 2016; 24: 213-220.
29. Cipriani G,
Vedovello M, Ulivi M, et al.
Delusional misidentification syndromes and
dementia: a border zone between neurology and psychiatry. Am J Alzheimers Dis
Other Demen 2013; 28: 671-678.
30. Lanctot KL,
Aguera-Ortiz L, Brodaty H, et al. Apathy associated with neurocognitive
disorders: recent progress and future directions. Alzheimers Dement 2017; 13:
84-100.
31. Robert PH,
Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and
awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive
impairment. Int J Geriatr Psychiatry 2002; 17: 1099-1105.
32. Van der Linde
RM, Matthews FE, Dening T, et al. Patterns and persistence of behavioural and
psychological symptoms in those with cognitive impairment: the importance of
apathy.
Int J Geriatr Psychiatry. Epub ahead of
print 27 March 2016. DOI: 10.1002/gps.4464.
33. Bubu OM,
Brannick M, Mortimer J, et al.
Sleep, cognitive impairment and Alzheimer’s
disease: a systematic review and meta-analysis.
Sleep 2017; 40: zsw032.
34. Ooms S and
Ju YE. Treatment of sleep disorders in dementia. Curr Treat Options Neurol 47.
2016; 18: 40.
35. McCleery J,
Cohen DA and Sharpley AL. Pharmacotherapies for sleep disturbances in dementia.
Cochrane Database Syst Rev 2016; 16: CD009178.
36. Heller J,
Brcina N, Dogan I, et al. Brain imaging findings in idiopathic REM sleep
behavior disorder (RBD): a systematic review on potential biomarkers for
neurodegeneration. Sleep Med Rev. Epub ahead of print 25 June 2016. DOI:
10.1016/j.smrv.2016.06.006.
37. Cagnin A,
Fragiacomo F, Camporese G, et al. Sleep-wake profile in dementia with Lewy
bodies, Alzheimer’s disease and normal aging. J Alzheimer Dis 2016; 55:
1529-1536.
38. McCarter SJ,
St Louis EK and Boeve BF. Sleep disturbances in frontotemporal dementia. Curr
NeurolNeurosci Rep 2016; 16: 85.
39. Mitchell AJ.
Neuropsychiatry and behavioural neurology explained. Edinburgh: Saunders, 2004,
p.536.
40. Bizdan M,
Bidzan L and Pachalska M. Neuropsychiatric symptoms in patients with
Alzheimer’s disease with a vascular component. Ann Agric Environ Med 2014; 21:
412-415.
41. Kazui H,
Yoshiyama K, Kanemoto H, et al. Differences of behavioral and psychological
symptoms of dementia in disease severity in four major dementias. PLoS One
2016; 11: e0161092.
42. Bang J,
Spina S and Miller BL. Frontotemporal dementia. Lancet 2015; 386: 1672-1682.
43. Clerc MT and
Von Gunten A. Frontotemporal lobar degeneration. In: Tanner P (eds) Dementia:
prevalence, risk factors and management strategies. Hauppauge (Headquarters),
New York: Nova Science Publishers, 2014,
pp.87-114.
44. Engelborghs
S, Vloeberghs E, Le Bastard N,
et al. The dopaminergic neurotransmitter
system is associated with aggression and agitation in frontotemporal dementia.
Neurochem Int 2008; 52: 1052-1060.
45. Von Gunten A,
Bouras C, Kovari E, et al. Neural substrates of cognitive and behavioral
deficits in atypical Alzheimer’s disease. Brain Res Rev 2006; 51: 176-211.
46. Huey ED, Lee
S and Devanand DP. Brain regions involved in arousal and reward processing are
associated with apathy in Alzheimer’s disease and frontotemporal dementia. J
Alzheimer Dis 2016; 55: 551-558.
Torso M, Serra L, Giulietti G, et al.
Strategic lesions in the anterior thalamic radiation and
10
OP Tible, F Riese et al.
apathy in early Alzheimer’s disease. PLoS
One 2015; 10: e0124998.
48. Makovac E,
Serra L, Spano B, et al. Different patterns of correlation between grey and
white matter integrity account for behavioral and psychological symptoms in
Alzheimer’s disease. J Alzheimers Dis 2016; 50: 591-604.
49. Tokuchi R,
Hishikawa N, Sato K, et al. Age- dependent cognitive and affective differences
in Alzheimer’s and Parkinson’s diseases in relation to MRI findings. J Neurol
Sci 2016; 365: 3-8.
50. Minger SL,
Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral
disturbance in patients with dementia. Neurology 2000; 55: 1460-1467.
51. Lagarde J,
Sarazin M, Chauvire V, et al. Cholinergic changes in aging and Alzheimer
disease: an 18F-F-A 85380 exploratory PET study. Alzheimer Dis Assoc Disord.
Epub ahead of print 27 September 2016. DOI: 10.1097/ WAD000000000163.
52. Herrmann N,
Lanctot KL and Khan LR.
The role of norepinephrine in the
behavioral and psychological symptoms of dementia. J
Neuropsychiatry Clin Neurosci 2004; 16:
261-276.
53. David R,
Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate
with apathy in neurodegenerative diseases: a SPECT study with partial volume
effect correction. Clin Neurol Neurosurg 2008; 110: 19-24.
54. Mitchell RA,
Herrmann N and Lanctot KL. The role of dopamine in symptoms and treatment of
apathy in Alzheimer’s disease. CNS Neurosci Ther 2011; 17: 411-427.
55. Gould E.
Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999; 21(Suppl.
2): 46S-51S.
56. Poletti S,
Locatelli C, Falini A, et al. Adverse childhood experiences associate to
reduced glutamate levels in the hippocampus of patients affected by mood
disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71: 117-122.
57. Ribeiro FM,
Vieira LB, Pires RG, et al. Metabolic glutamate receptors and neurodegenerative
diseases. Pharmacol Res 2016; 115: 179-191.
58. Maidment ID,
Haw C, Stubbs J, et al. Medication errors in older people with mental health
problems: a review. Int J Geriatr Psychiatry 2008; 23: 564-573.
59. Yesavage JA,
Noda A and Hernandez B. Circadian clock gene polymorphisms and
sleep-wake disturbance in Alzheimer
disease. Am J Geriatr Psychiatry 2011; 19: 635-643.
60. Mulin E,
Zeitzer JM, Yesavage J, et al. Relationship between apathy and sleep
disturbance in mild and moderate Alzheimer’s disease: an actigraphic study. J
Alzheimers Dis 2011; 25: 85-91.
61. Zheng Z, Wang
J, Yi L, et al. Correlation between behavioural and psychological symptoms of
Alzheimer type dementia and plasma homocysteine concentration. Biomed Res Int
2014: 383494.
62. Flirski M,
Sobow T and Kloszewska I. Behavioural genetics of Alzheimer’s disease: a
comprehensive review. Arch Med Sci 2011; 7: 195-210.
63. Kolaczkowski
M, Marcinkowska M, Bucki A, et al. Novel 5-HT6 receptor antagonists/D2 receptor
partial agonists targeting behavioral and psychological symptoms of dementia.
Eur J Med Chem 2015; 92: 221-235.
64. Stefano P,
Concetta C, Luigi D, et al. Role of neurodevelopment involved genes in
psychiatric comorbidities and modulation of inflammatory processes in Alzheimer’s
disease. J Neurol Sci 2016; 370: 162-166.
65. Tible O.
Presentation des equipes mobiles de Psychogeriatrie, Brussels, Belgium, 7-9
September 2016. Societe de Psychogeriatrie de Langue Frangaise, 32eme Congres
de Psychogeriatrie de langue frangaise, pp.25-26, www.splf-2016.org (accessed 9 September
2016).
66. Malara A, De
Biase GA, Bettarini F, et al.
Pain assessment in elderly with behavioral
and psychological symptoms of dementia. J Alzheimers Dis 2016; 50: 1217-1225.
67. Pocnet C,
Rossier J, Antonietti JP, et al. Personality changes in patients with beginning
Alzheimer disease. Can J Psychiatry 2011; 56: 408-417.
68. Pocnet C,
Rossier J, Antonietti JP, et al. Personality traits and behavioral and
psychological symptoms in patients at an early stage of Alzheimer’s disease.
Int J Geriatr Psychiatry 2013; 28: 276-283.
69. Prior J,
Abraham R, Nicholas H, et al.
Are premorbid abnormal personality traits
associated with behavioural and psychological symptoms in dementia? Int J
Geriatr Psychiatry 2016; 31: 1050-1055.
70. Boyle LL,
Lyness JM, Duberstein PR, et al.
Trait neuroticism, depression, and
cognitive function in older primary care patients. Am J Geriatr Psychiatry
2010; 18: 305-312.
11
Therapeutic Advances in Neurological
Disorders 00(0)
71. Johansson L,
Guo X, Duberstein PR, et al. Midlife personality and risk of Alzheimer disease
and distress: a 38-year follow-up. Neurology 2014; 83: 1538-1544.
72. Von Gunten A,
Pocnet C and Rossier J.
The impact of personality characteristics
on the clinical expression in neurodegenerative disorders: a review. Brain Res
Bull 2009; 80: 179-191.
73. Hirshfeld-Becker
DR, Micco J, Henin A, et al. Behavioral inhibition. Depress Anxiety 2008; 25:
357-367.
74. Schwartz CE,
Hirshfeld-Becker DR, Henin A, et al. Behavioral inhibition in childhood
predicts smaller hippocampal volume in adolescent offspring of parents with
panic disorder. Transl Psychiatry 2015; 21: e605.
75. Van Rooij SJ,
Kennis M, Vink M, et al. Childhood trauma and COMT genotype interact to
increase hippocampal activation in resilient individuals. Front Psychiatry
2016; 14: 156.
76. Bradley JM
and Cafferty TP. Attachment among older adults: current issues and directions
for future research. Attachment Hum Dev 2001; 3: 200-221.
77. Browne CJ and
Shlosberg E. Attachment theory, ageing and dementia: a review of the
literature. Aging Ment Health 2006; 10: 134-142.
78. Magai C, Cohen
CI, Culver C, et al. Relation between premorbid personality and patterns of
emotion expression in mid- to late-stage dementia. Int J Geriatr Psychiatry
1997; 12: 1092-1099.
79. Fujii M,
Butler JP and Sasaki H. Emotional function dementia patients. Psychogeriatrics
2014; 14: 202-209.
80. Feast A,
Orrell M, Russell I, et al. The contribution of caregiver psychosocial factors
to distress associated with behavioral and psychological symptoms in dementia.
Int J Geriatr Psychiatry 2017; 32: 76-85.
81. Corbett A,
Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with
dementia. Nat Rev Neurol 2012; 8: 264-274.
82. Ouslander J, Bartesl S, Beck C, et al.
Consensus
statement on
improving the quality of mental
health care in US
nursing homes: management
of depression and
behavioral symptoms
associated with
dementia. J Am Geriatr Soc
2003; 51:
1287-1298.
83. S3-Leitlinie
Demenzen. In: Deutsche Gesellschaft fur Neurologie, HRSG;
Leitlinien fur Diagnostik und Therapie in
der Neurologie, www.dgn.org/leitlinien (2016,
accessed 27 January 2016).
84. Livingston G,
Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation
in dementia: systematic review of randomized controlled trials. Br J Psychiatry
2014; 205: 436-442.
85. Abraha I,
Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of
non-pharmacological interventions to treat behavioural disturbances in older
patients with dementia. The SENATOR-On Top series. BMJ Open 2017; 7: 3:e012759.
86. Livingston G,
Johnston K, Katona C, et al. Systematic review of psychological approaches to
the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;
162: 1996-2021.
87. Hepburn K,
Lewis M, Tornatore J, et al. The Savvy Caregiver program: the demonstrated
effectiveness of a transportable dementia caregiver programme. J GerontolNurs
2007; 33: 30-36.
88. Copper C,
Mukadam N, Katona C, et al. Systematic review of the effectiveness of non-
pharmacological interventions to improve quality of life of people with
dementia. Int Psychogeriatr 2012; 24: 856-870.
89. Schoenmakers
B, Buntinx F and DeLepeleire J. Supporting the dementia family caregiver: the
effect of home care intervention on general wellbeing. Aging Ment Health 2010;
14: 44-56.
90. Kolanowski A.
An overview of the need-driven dementia-compromised behavior model. J Gerontol
Nurs 1999; 25: 7-9.
91. Kovach CR,
Noonan PE, Schlidt AM, et al.
The serial trial intervention: an
innovative approach to meeting needs of individuals with dementia. J Gerontol
Nurs 2006; 32: 18-25.
92. McMinn B and
Draper B. Vocally disruptive behaviour in dementia: development of an evidence
based practice guideline. Aging Ment Health 2005; 9: 16-24.
93. Hajjar RR and
Kamel HK. Sexuality in the nursing home, part 1: attitudes and barriers to
sexual expression. J Am Med Dir Assoc 2004; 5: 42-47.
94. Heyn P,
Abreu BC and Ottenbacher KJ. The effects of exercise training on elderly
patients with cognitive impairment and dementia: a
12
OP Tible, F Riese et al.
meta-analysis. Arch Phys Med Rehabil 2004;
85: 1694-1704.
95. Scholey KA
and Woods BT. A series of brief 105 cognitive therapy interventions with people
experiencing both dementia and depression: a description of techniques and
common themes.
Clin Psychol Psychiatry 2003; 10: 175-185.
96. Brodaty H and
Arasaratnam C. Meta-analysis 106 of nonpharmacological interventions for
neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169: 946-953.
97. Sorensen S,
Pinquart M and Duberstein P.
How effective are interventions with
caregivers?
An updated meta-analysis. Gerontologist
2002; 107 42: 356-372.
98. Trinh NH,
Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the
treatment
of neuropsychiatric symptoms and functional
108 impairment in Alzheimer’s disease: a metaanalysis. JAMA 2003;
289: 210-216.
99. Howard RJ,
Juszczak E, Ballard CG, et al.
Donepezil for the treatment of agitation in
Alzheimer’s disease. N Engl J Med 2007; 357: 109 1382-1392.
100. Gauthier
S, Loft H and Cummings J.
Improvement in behavioural symptoms in
patients with moderate to severe Alzheimer’s
disease by memantine: a pooled data
analysis. 110
Int J Geriatr Psychiatry 2008; 23: 537-545.
101. Wilcock
GK, Ballard CG, Cooper JA, et al.
Memantine for
agitation/aggression and psychosis in moderately severe to severe Alzheimer’s
disease: a pooled analysis of 3 111
studies. J Clin Psychiatry 2008; 69:
341-348.
102. Von
Gunten A. Schwabe Symposium on BPSD: prevalence, clinical importance and
treatment options. Second Congress of the European Academy of Neurology, 28-31
May 2016, 112. Copenhagen, Denmark, www.ean.org (accessed
31 May 2016).
103. Fox C,
Crugel M, Maidment I, et al. Efficacy
of memantine for
agitation in Alzheimer’s 113
dementia: a randomized double-blind placebo
controlled trial. PLoS One 2012; 7: e35185.
104. Ballard C, Thomas A,
Gerry S, et al. A
double-blind
randomized placebo-controlled 114
withdrawal
trial comparing memantine and
antipsychotics
for the long-term treatment of
function
and neuropsychiatric symptoms in
people with Alzheimer’s disease (MAIN-AD).
J Am Med Dir Assoc 2015; 16: 316-322.
Von Gunten A, Schlaefke S and Uberla K.
Efficacy of Gingko Biloba extract EGb 761® in dementia with behavioural and
psychological symptoms: a systematic review. World J Biol Psychiatry 2016; 17:
622-633.
Lyketsos CG, Del Campo L, Steinberg M, et
al. Treating depression in Alzheimer disease: efficacy and safety of sertraline
therapy, and the benefits of depression reduction: the DIADS. Arch Gen
Psychiatry 2003; 60: 737-746.
Porsteinsson AP, Drye LT, Pollock BG, et
al. Effect of citalopram on agitation in Alzheimer disease: the citAD
randomized clinical trial. JAMA 2014; 311: 682-691.
Ballard C and Waite J. The effectiveness of
atypical antipsychotics for the treatment of aggression and psychosis in
Alzheimer’s disease. Cochrane Database Syst Rev 2006; 25: CD003476.
Maher AR, Maglione M, Bagley S, et al.
Efficacy and comparative effectiveness of
atypical antipsychotic medications for off-label uses in adults: a systematic
review and metaanalysis. JAMA 2011; 306: 1359-1369.
Reus VI, Fochtmann LJ, Eyler AE, et al. The
American Psychiatric Association practice guideline on the use of
antipsychotics to treat agitation or psychosis in patients with dementia. Am J
Psychiatry 2016; 173: 543-546.
Tariot PN, Schneider L, Katz IR, et al.
Quetiapine treatment of psychosis associated with dementia: a double-blind,
randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006;
14: 767-776.
Kurlan R, Cummings J, Raman R, et al.
Quetiapine for agitation or psychosis in patients with dementia and
parkinsonism. Neurology 2007; 68: 1356-1363.
Ballard CG, Gauthier S, Cummings JL, et al.
Management of agitation and aggression associated with Alzheimer disease. Nat
Rev Neurol 2009; 5: 245-255.
Zhou QP, Jung L and Richards KC. The
management of sleep and circadian disturbance in patients with dementia. Curr
Neurol Neurosci Rep 2012; 12: 193-204.
Visit SAGE journals online
®SAGE journals
13